In Brief: Centeon/Medarex
Centeon/Medarex: Companies will jointly develop MDX-33, a humanized monoclonal antibody for the treatment of autoimmune hematological disorders. Centeon will finance product development through Phase II trials up to $20 mil., as well as Phase III trials, regulatory approvals and launch costs. Centeon will pay Medarex $1 mil. for technology access, nearly $1 mil. for R&D funding for manufacturing improvements, and $10 mil. for achieving specific milestones. Centeon, a Rhone-Poulenc Rorer and Hoechst AG joint venture, will have exclusive marketing rights to MDX-33; Medarex will receive royalties...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth